Browse News

Found 290 articles

• Fulcrum Therapeutics to Participate at the Cantor Fitzgerald Global Healthcare Conference

  9/22/2023

  Fulcrum Therapeutics, Inc. ® today announced that management will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference, being held in New York, NY on Thursday, September 28, 2023 at 8:35 a.m. ET.

• Accent Therapeutics Bolsters Leadership Team with Key Executive Hires

  9/21/2023

  Accent Therapeutics today announced the appointments of Jason Sager, M.D. as Chief Medical Officer, Steven Mennen, Ph.D., as Vice President of Pre-Clinical Development and Stuart Ince, Ph.D. as Vice President of Program Leadership.

• Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 15, 2023

  9/15/2023

  Fulcrum Therapeutics, Inc.®, a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that the company granted non-statutory stock options to new employees.

• Adagio Medical Announces Initiation and First Procedure in FULCRUM-VT Trial, Starting The Process For Bringing Ultra-Low Temperature Cryoablation for Ventricular Arrhythmias to US Market

  9/13/2023

  Adagio Medical, Inc. announced the first ultra-low temperature cryoablation (ULTC) procedure performed using the Adagio vCLAS™ catheter system in the United States as part of the FULCRUM-VT (Feasibility of Ultra-Low Temperature Cryoablation for Recurring Monomorphic Ventricular Tachycardia) clinical trial, NCT # NCT05675865.

• Wave of FDA Fast Track Designations Highlight Biotech Momentum Carrying into 2023

  9/13/2023

  Sufferers of many different ailments saw reason to grow their hope in 2022 when the US Food and Drug Administration (FDA) granted several approvals and new Fast Track designations towards the end of 2022 and into January of 2023.

• Fulcrum Announces Completion of Enrollment in the Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)

  9/7/2023

  Fulcrum Therapeutics, Inc. today announced that it has completed enrollment in REACH, a Phase 3 clinical trial evaluating losmapimod in patients with FSHD at sites in the United States, Canada, and Europe.

• Pairwise, Bayer Build on Successful Gene Editing Partnership With New Five-Year, Multi-Million Dollar Collaboration to Further Advance Short-Stature Corn

  8/29/2023

  Pairwise, a food and agriculture company known for bringing the first gene-edited food to the U.S. market, and Bayer announced a new five-year, multi-million Dollar agreement focused on innovations in short-stature corn.

• 

  Fulcrum’s Sickle Cell Trial Given Greenlight to Proceed After Hold

  8/22/2023

  The FDA has lifted the clinical hold it had placed on the Phase Ib study following the occurrence of hematological malignancies.

• FDA Lifts Clinical Hold on Fulcrum Therapeutics’ FTX-6058 for Sickle Cell Disease

  8/22/2023

  Fulcrum Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Investigational New Drug (IND) application for FTX-6058 for the potential treatment of sickle-cell disease (SCD).

• Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - August 11, 2023

  8/11/2023

  Fulcrum Therapeutics, Inc.® announced that the company granted non-statutory stock options to Alan Musso, the company’s newly appointed chief financial officer, as well as one other new employee.

• Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2023

  8/3/2023

  Fulcrum Therapeutics, Inc.®, a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, reported financial results for the second quarter of 2023 and provided a business update.

• Fulcrum Therapeutics Appoints Chief Financial Officer

  8/3/2023

  Fulcrum Therapeutics, Inc.®, a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced the appointment of Alan A. Musso as chief financial officer, effective August 7, 2023.

• Fulcrum Therapeutics to Host Second Quarter 2023 Financial Results Conference Call and Webcast on Thursday, August 3, 2023, at 8:00 a.m. ET

  7/27/2023

  Fulcrum Therapeutics, Inc. today announced that its second quarter 2023 financial results will be released on Thursday, August 3, 2023 before the U.S. financial markets open.

• Atavistik Bio Appoints Bryan Stuart as Chief Executive Officer

  7/17/2023

  Atavistik Bio today announced the appointment of Bryan Stuart as Chief Executive Officer (CEO) and a Director on the company’s Board.

• Rarebase Announces Promotion of Chris Moxham to President

  7/13/2023

  Rarebase today announced the promotion of Chris Moxham, Ph.D., to the newly created role of President effective immediately.

• Fulcrum Therapeutics Signs Exclusive Global License Agreement in Rare Hematology CAMP4 Therapeutics grants exclusive rights to advance novel therapies for Diamond-Blackfan Anemia

  7/10/2023

  Fulcrum Therapeutics, Inc. today announced that it has entered into a worldwide, exclusive license agreement with CAMP4 Therapeutics Corp., whereby Fulcrum will advance the discovery, development, and commercialization of novel therapeutic agents against an undisclosed target for the potential treatment of Diamond-Blackfan Anemia (DBA).

• Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 07, 2023

  7/7/2023

  Fulcrum Therapeutics, Inc.® announced that the Company granted non-statutory stock options to a new employee.

• Bionomics Announces Key Leadership Updates to Drive U.S.-Focused Transformation and Next Stage of Strategic Growth

  7/3/2023

  Bionomics Limited announced key leadership updates to drive its ongoing transformation to a U.S.-focused company, streamline its allocation of capital, and support its next stage of strategic growth.

• Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 09, 2023

  6/9/2023

  Fulcrum Therapeutics, Inc.®, a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that the Company granted non-statutory stock options to new employees.

• Fulcrum Therapeutics Appoints Alex C. Sapir Chief Executive Officer

  5/15/2023

  Fulcrum Therapeutics, Inc.®, a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced the appointment of Alex C. Sapir as chief executive officer and president, effective July 1st, 2023.